Pure Global

Prophylactic Effects for Preventing Surgical Site Infection in Third Molar Surgery - Trial NCT06368102

Access comprehensive clinical trial information for NCT06368102 through Pure Global AI's free database. This Phase 4 trial is sponsored by Uji Takeda Hospital and is currently Recruiting. The study focuses on Surgical Site Infection. Target enrollment is 70 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06368102
Phase 4
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06368102
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Prophylactic Effects for Preventing Surgical Site Infection in Third Molar Surgery
Prophylactic Effects of Different Duration of Intravenous Ampicillin for Preventing Surgical Site Infection in Third Molar Surgery: a Randomized Controlled Trial

Study Focus

Surgical Site Infection

Ampicillin

Interventional

drug

Sponsor & Location

Uji Takeda Hospital

Uji, Japan

Timeline & Enrollment

Phase 4

May 02, 2024

Aug 01, 2025

70 participants

Primary Outcome

Occurrence of surgical site infection

Summary

The purpose of this study is to determine the incidence of surgical site infection (SSIs)
 after third molar surgery for different duration of intravenous ampicillin administration.

ICD-10 Classifications

Infection following a procedure, not elsewhere classified
Bacterial infection of unspecified site
Other bacterial infections of unspecified site
Infection of obstetric surgical wound
Other specified local infections of skin and subcutaneous tissue

Data Source

ClinicalTrials.gov

NCT06368102

Non-Device Trial